Tag results:
β-cells
Mesenchymal Cell News
Distinct Roles of KLF4 in Mesenchymal Cell Subtypes during Lung Fibrogenesis
[Nature Communications] Researchers indicated that KLF4 played opposing roles in platelet-derived growth factor receptor-β+ cells and α-smooth muscle actin+ cells and highlighted the importance of further studies of interactions between distinct mesenchymal cell types.
Mesenchymal Cell News
Gastrin Producing Syngeneic Mesenchymal Stem Cells Protect Non-obese Diabetic Mice from Type 1 Diabetes
[Autoimmunity] Scientists reported the use of MSCs for the production and delivery of Gastrin, a peptide hormone that is produced by intestinal cells and fetal islets and can increase β-cell mass, to promote protection from type 1 diabetes.
Pancreatic Cell News
L-methionine Prevents β-Cell Damage by Modulating the Expression of Arx, MafA and Regulation of FOXO1 in Type 1 Diabetic Rats
[Acta Histochemica] Researchers investigated the effect of L-Met on streptozotocin-induced β-cell damage model of diabetes mellitus in Sprague Dawley rats. At the end of study biochemical parameters, immunoblotting, qRT-PCR and ChIP-qPCR were performed.
Pancreatic Cell News
Artemether and Aspterric Acid Induce Pancreatic α Cells to Transdifferentiate into β Cells in Zebrafish
[British Journal of Pharmacology] Investigators used the Cre-LoxP system for lineage tracing to indicate the conversion of α cells into β cells in vivo. The stable transgenic ins2:eGFP αTC1-6 cell line were used for evaluation of α cell transdifferentiation in vitro.
Pancreatic Cell News
Microtubules Regulate Pancreatic β-Cell Heterogeneity via Spatiotemporal Control of Insulin Secretion Hot Spots
[eLife] Researchers indicate that microtubules (MTs) stability in the β-cell population was heterogenous, and that glucose-stimulated insulin secretion was suppressed in cells with highly stable MTs.
Cell Therapy News
Implanted Pluripotent Stem-Cell-Derived Pancreatic Endoderm Cells Secrete Glucose-Responsive C-peptide in Patients with Type 1 Diabetes
[Cell Stem Cell] The authors reported an analysis on one year of data from the first cohort of 15 patients from a single trial site that received subcutaneous implantation of cell products combined with an immunosuppressive regimen.